BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114. [PMID: 31269959 DOI: 10.1186/s12943-019-1043-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Leung JY, Chia K, Ong DST, Taneja R. Interweaving Tumor Heterogeneity into the Cancer Epigenetic/Metabolic Axis. Antioxid Redox Signal 2020;33:946-65. [PMID: 31841357 DOI: 10.1089/ars.2019.7942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y, Qiu Y, Zhang Z, Li M, Jiang Y, Zhao J, Du H, Zhang Z, Lu W, Zhang Y. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. Biomed Res Int 2020;2020:4037639. [PMID: 33163533 DOI: 10.1155/2020/4037639] [Reference Citation Analysis]
3 Zhang J, Yuan Y, Gao S, Zhao X, Li H. Diagnostic performance of circulating cell-free DNA for hepatocellular carcinoma: a systematic review and meta-analysis. Biomark Med 2021;15:219-39. [PMID: 33470842 DOI: 10.2217/bmm-2020-0334] [Reference Citation Analysis]
4 Vasantharajan SS, Eccles MR, Rodger EJ, Pattison S, McCall JL, Gray ES, Calapre L, Chatterjee A. The Epigenetic landscape of Circulating tumour cells. Biochim Biophys Acta Rev Cancer 2021;1875:188514. [PMID: 33497709 DOI: 10.1016/j.bbcan.2021.188514] [Reference Citation Analysis]
5 Wang Y, Li B, Tian T, Liu Y, Zhang J, Qian K. Advanced on-site and in vitro signal amplification biosensors for biomolecule analysis. TrAC Trends in Analytical Chemistry 2022. [DOI: 10.1016/j.trac.2022.116565] [Reference Citation Analysis]
6 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
7 Chen F, Wang D, Chen J, Ling J, Yue H, Gou L, Tang H. PtNi nanocubes-catalyzed tyramine signal amplification electrochemiluminescence sensor for nonenzymatic and ultrasensitive detection of hepatocellular carcinoma cells. Sensors and Actuators B: Chemical 2020;305:127472. [DOI: 10.1016/j.snb.2019.127472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
8 Rho YS, Pagano I, Wong LL, Kwee SA, Acoba JD. Factors and Survival Implications associated with biopsy of hepatocellular carcinoma. HPB (Oxford) 2021;23:1054-60. [PMID: 33229278 DOI: 10.1016/j.hpb.2020.11.001] [Reference Citation Analysis]
9 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xiao R, Liu C, Zhang B, Ma L. Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma. Front Oncol 2022;12:844520. [DOI: 10.3389/fonc.2022.844520] [Reference Citation Analysis]
11 Yang JC, Hu JJ, Li YX, Luo W, Liu JZ, Ye DW. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Front Oncol 2022;12:781820. [PMID: 35211399 DOI: 10.3389/fonc.2022.781820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Arechederra M, Recalde M, Gárate-Rascón M, Fernández-Barrena MG, Ávila MA, Berasain C. Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers (Basel) 2021;13:1265. [PMID: 33809263 DOI: 10.3390/cancers13061265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu GQ, Liu WR, Tang Z, Qu WF, Fang Y, Jiang XF, Song SS, Wang H, Tao CY, Zhou PY, Huang R, Gao J, Sun HX, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Shi YH. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Mol Oncol 2021. [PMID: 34543520 DOI: 10.1002/1878-0261.13105] [Reference Citation Analysis]
15 Huang Z, Yang F, Huang Y, Lin X, Feng W, Tian X. Sorting and identification of circulating tumor cells of gliomas with EGFR antibody-modified immunomagnetic microspheres. AIP Advances 2021;11:025141. [DOI: 10.1063/5.0037919] [Reference Citation Analysis]
16 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
17 Liu Z, Ma H, Lai Z. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology. BMC Complement Med Ther 2021;21:263. [PMID: 34663301 DOI: 10.1186/s12906-021-03425-9] [Reference Citation Analysis]
18 Zhang T, Yin M, Wang L, Cao W, Zhong S. Diagnostic performance of blood-based liquid biopsies in hepatocellular carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22594. [PMID: 33031312 DOI: 10.1097/MD.0000000000022594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Li X, Wang H, Li T, Wang L, Wu X, Liu J, Xu Y, Wei W. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer 2020;44:100516. [PMID: 31836136 DOI: 10.1016/j.currproblcancer.2019.100516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Jeffrey GP, Gordon LG, Hill MM, Ramm GA. Liquid Biopsies for Hepatocellular Cancer and Their Potential in Clinical Practice. Hepatology 2020;71:2160-2. [PMID: 32031686 DOI: 10.1002/hep.31168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
21 Ju X, Tang Y, Qu R, Hao S. The Emerging Role of Circ-SHPRH in Cancer. Onco Targets Ther 2021;14:4177-88. [PMID: 34285509 DOI: 10.2147/OTT.S317403] [Reference Citation Analysis]
22 Ueno A, Masugi Y, Yamazaki K, Kurebayashi Y, Tsujikawa H, Effendi K, Ojima H, Sakamoto M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 2020;70:140-54. [PMID: 31908112 DOI: 10.1111/pin.12895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sorop A, Iacob R, Iacob S, Constantinescu D, Chitoiu L, Fertig TE, Dinischiotu A, Chivu-Economescu M, Bacalbasa N, Savu L, Gheorghe L, Dima S, Popescu I. Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening. Front Genet 2020;11:712. [PMID: 32793278 DOI: 10.3389/fgene.2020.00712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Reddy T, Esmail A, Chang JC, Ghobrial RM, Abdelrahim M. Utility of Cell-Free DNA Detection in Transplant Oncology. Cancers (Basel) 2022;14:743. [PMID: 35159010 DOI: 10.3390/cancers14030743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Reference Citation Analysis]
26 Li X, Zhao W, Peng L, Li Y, Nie S, Yu H, Qin Y, Zhang H. Elevated serum extracellular vesicle arginase 1 in type 2 diabetes mellitus: a cross-sectional study in middle-aged and elderly population. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-00982-z] [Reference Citation Analysis]
27 Karadag Soylu N. Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer 2020;51:1176-86. [PMID: 32844348 DOI: 10.1007/s12029-020-00499-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
28 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Du Z, Liu X, Wei X, Luo H, Li P, Shi M, Guo B, Cui Y, Su Z, Zeng J, Si A, Cao P, Zhou G. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma. Sci Rep 2020;10:15552. [PMID: 32968147 DOI: 10.1038/s41598-020-72510-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
30 Xia Y, Huang Z, Chen T, Xu L, Zhu G, Chen W, Chen G, Wu S, Lan J, Lin X, Chen J. Sensitive fluorescent detection of exosomal microRNA based on enzymes-assisted dual-signal amplification. Biosens Bioelectron 2022;209:114259. [PMID: 35421672 DOI: 10.1016/j.bios.2022.114259] [Reference Citation Analysis]
31 Zhang Y, Liu Z, Ji K, Li X, Wang C, Ren Z, Liu Y, Chen X, Han X, Meng L, Li L, Li Z. Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:736330. [PMID: 34660697 DOI: 10.3389/fmolb.2021.736330] [Reference Citation Analysis]
32 Zhou C, Sun J, Zheng Z, Weng J, Atyah M, Zhou Q, Chen W, Zhang Y, Huang J, Yin Y, Mao H, Zhang Z, Yi Y, Ren N. High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Ann Transl Med 2020;8:466. [PMID: 32395510 DOI: 10.21037/atm.2020.03.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Li H, Li M, Guo H, Lin G, Huang Q, Qiu M. Integrative Analyses of Circulating mRNA and lncRNA Expression Profile in Plasma of Lung Cancer Patients. Front Oncol 2022;12:843054. [DOI: 10.3389/fonc.2022.843054] [Reference Citation Analysis]
35 Shah D, Lamarca A, Valle JW, McNamara MG. The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. J Clin Med 2021;10:403. [PMID: 33494364 DOI: 10.3390/jcm10030403] [Reference Citation Analysis]
36 Xiong F, Zhu K, Deng S, Huang H, Yang L, Gong Z, Shi L, He Y, Tang Y, Liao Q, Yu J, Li X, Li Y, Li G, Zeng Z, Xiong W, Zhang S, Guo C. AFAP1-AS1: a rising star among oncogenic long non-coding RNAs. Sci China Life Sci 2021. [PMID: 33999309 DOI: 10.1007/s11427-020-1874-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Luo S, Ou Y, Zheng T, Jiang H, Wu Y, Zhao J, Zhang Z. Optimal Strategy for Colorectal Cancer Patients' Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9. J Oncol 2021;2021:1517488. [PMID: 34976053 DOI: 10.1155/2021/1517488] [Reference Citation Analysis]
38 Li H, Zhao J, Zhang J, Wang C, Li M, Wu S, Su Z, Pan Q. Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma. Exp Ther Med 2019;18:3389-96. [PMID: 31602213 DOI: 10.3892/etm.2019.7997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
39 Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 2020;72:990-1002. [PMID: 32044402 DOI: 10.1016/j.jhep.2020.01.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
40 Gouri A, Benarba B, Dekaken A, Aoures H, Benharkat S. Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers. Curr Drug Targets 2020;21:1008-25. [PMID: 32164510 DOI: 10.2174/1389450121666200312105908] [Reference Citation Analysis]
41 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Dominguez DA, Wang XW. Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really? J Hepatocell Carcinoma 2020;7:33-7. [PMID: 32257970 DOI: 10.2147/JHC.S217948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
43 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Song T, Li L, Wu S, Liu Y, Guo C, Wang W, Dai L, Zhang T, Wu H, Su B. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:583714. [PMID: 33777736 DOI: 10.3389/fonc.2021.583714] [Reference Citation Analysis]
45 Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Chen K, Liu X, Liu W, Wang F, Tian X, Yang Y. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets. Hum Mol Genet 2021:ddab343. [PMID: 34957503 DOI: 10.1093/hmg/ddab343] [Reference Citation Analysis]
47 Guo Y, Guo Y, Chen C, Fan D, Wu X, Zhao L, Shao B, Sun Z, Ji Z. Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis. Mol Cancer 2021;20:93. [PMID: 34172072 DOI: 10.1186/s12943-021-01372-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kirchweger P, Wundsam HV, Rumpold H. Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies. World J Clin Oncol 2022; 13(6): 473-484 [DOI: 10.5306/wjco.v13.i6.473] [Reference Citation Analysis]
49 Colquhoun SD. Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research 2020;4:180-90. [DOI: 10.1016/j.livres.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
51 Yu B, Zhou S, Liang H, Ye Q, Wang Y. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 33982217 DOI: 10.1007/s10620-021-07031-0] [Reference Citation Analysis]
52 Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S, Hu B, Zhang Z, Guo W, Cao Y, Huang X, Zhou J, Fan J, Yang X. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [DOI: 10.1111/liv.14734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
53 Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Reference Citation Analysis]
54 Zhou J, Zhang Z, Zhou H, Leng C, Hou B, Zhou C, Hu X, Wang J, Chen X. Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma. BMC Cancer. 2020;20:1047. [PMID: 33129301 DOI: 10.1186/s12885-020-07488-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wang J, Yang L, Diao Y, Liu J, Li J, Li R, Zheng L, Zhang K, Ma Y, Hao X. Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR. J Int Med Res 2021;49:300060521992962. [PMID: 33750234 DOI: 10.1177/0300060521992962] [Reference Citation Analysis]
56 Fu T, Li S, Wei L, Huang S, Xue Y, Cui K. Optimal whole blood dilution protocol for preprocessing samples prior to circulating tumor cell capture by size-based isolation. J Clin Lab Anal 2022;:e24524. [PMID: 35657145 DOI: 10.1002/jcla.24524] [Reference Citation Analysis]
57 Pan B, Yang M, Wei X, Li W, Wang K, Yang M, Lu D, Wang R, Cen B, Xu X. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma. Aging (Albany NY) 2021;13:18620-44. [PMID: 34282055 DOI: 10.18632/aging.203306] [Reference Citation Analysis]
58 Liu A, Wu Q, Peng D, Ares I, Anadón A, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Martínez MA. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev 2020;40:1973-2018. [PMID: 32525219 DOI: 10.1002/med.21696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
59 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
60 Wu TM, Liu JB, Liu Y, Shi Y, Li W, Wang GR, Ma YS, Fu D. Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control. Cancer Control 2020;27:1073274820934805. [PMID: 32806937 DOI: 10.1177/1073274820934805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J, Li J, Li X, Jia Y, He T, Zhu J, Sun Y, Jiang W, Zhang H, Wang C, Ke Z. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer 2020;19:15. [PMID: 31980023 DOI: 10.1186/s12943-020-1141-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
62 Liu J, Zhao H, Huang Y, Xu S, Zhou Y, Zhang W, Li J, Ming Y, Wang X, Zhao S, Li K, Dong X, Ma Y, Qian T, Chen X, Xing Z, Zhang Y, Chen H, Liu Z, Pang D, Zhou M, Wu Z, Wang X, Wang X, Wu N, Su J. Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer. Mol Cancer 2021;20:36. [PMID: 33608029 DOI: 10.1186/s12943-021-01330-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Zhu B, Gu S, Wu X, He W, Zhou H. Bioinformatics analysis of tumor-educated platelet microRNAs in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20211420. [PMID: 34806748 DOI: 10.1042/BSR20211420] [Reference Citation Analysis]
64 Cai Z, Zhang J, He Y, Xia L, Dong X, Chen G, Zhou Y, Hu X, Zhong S, Wang Y, Chen H, Xie D, Liu X, Liu J. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO Open 2021;6:100021. [PMID: 33508734 DOI: 10.1016/j.esmoop.2020.100021] [Reference Citation Analysis]
65 Zhao L, Wu X, Li T, Luo J, Dong D. ctcRbase: the gene expression database of circulating tumor cells and microemboli. Database (Oxford) 2020;2020:baaa020. [PMID: 32294193 DOI: 10.1093/database/baaa020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
66 Vogl TJ, Riegelbauer LJ, Oppermann E, Kostantin M, Ackermann H, Trzmiel A, Stein S, Eichler K, Zharov VP, Roy D, Schnitzbauer AA, Strücker B, Pascher A, Bechstein WO, Juratli MA. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma. PLoS One 2021;16:e0246527. [PMID: 33577574 DOI: 10.1371/journal.pone.0246527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Vyas M, Zhang X. Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:591-610. [DOI: 10.1016/j.cld.2020.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, Zhou J. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther 2021;6:404. [PMID: 34803167 DOI: 10.1038/s41392-021-00817-8] [Reference Citation Analysis]
69 Jing Z, Chen K, Gong L. The Significance of Exosomes in Pathogenesis, Diagnosis, and Treatment of Esophageal Cancer. Int J Nanomedicine 2021;16:6115-27. [PMID: 34511909 DOI: 10.2147/IJN.S321555] [Reference Citation Analysis]
70 Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers (Basel) 2021;13:4334. [PMID: 34503144 DOI: 10.3390/cancers13174334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer 2022;21:56. [PMID: 35180868 DOI: 10.1186/s12943-022-01509-9] [Reference Citation Analysis]
72 Yu J, Shi X, Yu H, Wu J, Ma J, Dong S, Lu S, Zheng S, Li L, Xu X, Cao H. Impact of hepatitis B surface antigen positive grafts on liver transplantation in patients with benign and malignant liver disease. J Med Virol 2022. [PMID: 35257389 DOI: 10.1002/jmv.27703] [Reference Citation Analysis]
73 Carissimi F, Barbaglia MN, Salmi L, Ciulli C, Roccamatisi L, Cordaro G, Mallela VR, Minisini R, Leone BE, Donadon M, Torzilli G, Pirisi M, Romano F, Famularo S. Finding the seed of recurrence: Hepatocellular carcinoma circulating tumor cells and their potential to drive the surgical treatment. World J Gastrointest Surg 2021; 13(9): 967-978 [PMID: 34621473 DOI: 10.4240/wjgs.v13.i9.967] [Reference Citation Analysis]
74 Luo Q, Wang C, Peng B, Pu X, Cai L, Liao H, Chen K, Zhang C, Cheng Y, Pan M. Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. Front Oncol. 2020;10:1758. [PMID: 33224869 DOI: 10.3389/fonc.2020.01758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Cheng G, Li M, Ma X, Nan F, Zhang L, Yan Z, Li H, Zhang G, Han Y, Xie L, Guo X. Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma. Front Oncol 2020;10:543817. [PMID: 33344224 DOI: 10.3389/fonc.2020.543817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 58.0] [Reference Citation Analysis]
77 Chang Y, Liu B, Niu H, Wang Z, Xia S, Li H. Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: Evidence from a meta-analysis. Medicine (Baltimore) 2020;99:e21887. [PMID: 32846849 DOI: 10.1097/MD.0000000000021887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida I, Yamasaki T. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun 2020;4:461-70. [PMID: 32140662 DOI: 10.1002/hep4.1469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
79 Best MG, Wurdinger T. Tumor-educated platelets for the earlier detection of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2020;44:794-5. [PMID: 32335046 DOI: 10.1016/j.clinre.2020.03.028] [Reference Citation Analysis]
80 Zhao G, Zhou A, Li X, Zhu S, Wang Y, Zhang S, Li P. The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer. Genes (Basel) 2021;12:73. [PMID: 33430032 DOI: 10.3390/genes12010073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Peng C, Li Z, Xie Z, Wang Z, Ye Y, Li B, Li W. The role of circulating microRNAs for the diagnosis of hepatitis B virus-associated hepatocellular carcinoma with low alpha-fetoprotein level: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:249. [PMID: 32736604 DOI: 10.1186/s12876-020-01345-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
83 Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Reference Citation Analysis]
84 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
85 Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol 2020;10:1316. [PMID: 32923383 DOI: 10.3389/fonc.2020.01316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
86 Tao Y, Wang J, Xu X. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Front Bioeng Biotechnol 2020;8:184. [PMID: 32211399 DOI: 10.3389/fbioe.2020.00184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol 2021:S1044-579X(21)00050-X. [PMID: 33647386 DOI: 10.1016/j.semcancer.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
88 Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
90 Cao M, Li H, Sun D, He S, Yu Y, Li J, Chen H, Shi J, Ren J, Li N, Chen W. Cancer screening in China: The current status, challenges, and suggestions. Cancer Lett 2021;506:120-7. [PMID: 33684533 DOI: 10.1016/j.canlet.2021.02.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Hu M, Wang Z, Wu Z, Ding P, Pei R, Wang Q, Xing C. Circulating tumor cells in colorectal cancer in the era of precision medicine. J Mol Med (Berl) 2021. [PMID: 34802071 DOI: 10.1007/s00109-021-02162-3] [Reference Citation Analysis]
92 Xu C, Cao H, Shi C, Feng J. The Role Of Circulating Tumor DNA In Therapeutic Resistance. Onco Targets Ther 2019;12:9459-71. [PMID: 31807023 DOI: 10.2147/OTT.S226202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zhong H, Yuan C, He J, Yu Y, Jin Y, Huang Y, Zhao R. Engineering Peptide-Functionalized Biomimetic Nanointerfaces for Synergetic Capture of Circulating Tumor Cells in an EpCAM-Independent Manner. Anal Chem 2021;93:9778-87. [PMID: 34228920 DOI: 10.1021/acs.analchem.1c01254] [Reference Citation Analysis]
94 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Kattner AA. The best protection is early detection. Biomed J 2022:S2319-4170(22)00020-8. [PMID: 35042015 DOI: 10.1016/j.bj.2022.01.010] [Reference Citation Analysis]
96 Liao H, Huang W, Pei W, Li H. Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. Front Oncol 2020;10:587671. [PMID: 33384956 DOI: 10.3389/fonc.2020.587671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Kamal MM, Abdelaziz AO, El-Baz HN, Mohamed GM, Saleh SS, Nabeel MM, Elbaz TM, Lithy R, Shousha HI. Plasma cell-free DNA integrity index and hepatocellular carcinoma treated or not with direct-acting antivirals: A case-control study. Arab J Gastroenterol 2022:S1687-1979(21)00100-3. [PMID: 35120838 DOI: 10.1016/j.ajg.2021.12.006] [Reference Citation Analysis]
98 Moretti G, Aretini P, Lessi F, Mazzanti CM, Ak G, Metintaş M, Lando C, Filiberti RA, Lucchi M, Bonotti A, Foddis R, Cristaudo A, Bottari A, Apollo A, Del Re M, Danesi R, Mutti L, Gemignani F, Landi S. Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. Cancers (Basel) 2021;13:2445. [PMID: 34070018 DOI: 10.3390/cancers13102445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]